Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBHIAK)

Drug Name
PD-174265 Drug Info
Synonyms
pd 174265; 4-aminoquinazoline, 2a; PD-174265; CHEMBL188762; 4-[(3-Bromophenyl)amino]-6-propionylamidoquinazoline; N-{4-[(3-Bromophenyl)amino]quinazolin-6-Yl}propanamide; 3lok; 2hwp; AC1L1IS1; BMC163482 Compound 3; GTPL6017; SCHEMBL2944459; BDBM31826; WUPUZEMRHDROEO-UHFFFAOYSA-N; MolPort-044-561-456; HMS3229I05; ZINC1488953; IN1163; HSCI1_000122; CCG-206770; ACM216163530; N-[4-(3-bromoanilino)quinazolin-6-yl]propanamide; J-014179; N-(4-(3-bromophenylamino)quinazolin-6-yl)propionamide
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
4709
TTD Drug ID
DMBHIAK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Proto-oncogene c-Src (SRC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dasatinib DMJV2EK Chronic myelogenous leukaemia 2A20.0 Approved [3]
Bosutinib DMTI8YE Breast cancer 2C60-2C65 Approved [3]
SKI-758 DMQ8E9R Ischemia 8B10-8B11 Approved [4]
Herbimycin A DM6YWBF Solid tumour/cancer 2A00-2F9Z Approved [5]
Al3818 DM3WP0N Alveolar soft part sarcoma 2A60-2C35 Phase 3 [6]
CP-868596 DMZIM37 Gastrointestinal cancer 2C11 Phase 3 [6]
Masitinib DMRSNEU Amyotrophic lateral sclerosis 8B60.0 Phase 3 [7]
KX-01 DMF0NA9 Actinic keratosis EK90.0 Phase 3 [8]
Saracatinib DMBLHGP Hematologic tumour 2B33.Y Phase 2 [9]
TPX-0046 DMIVE67 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proto-oncogene c-Src (SRC) TT6PKBN SRC_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6017).
2 Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc. J Med Chem. 2009 Jul 9;52(13):3915-26.
3 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
4 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
5 In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
10 Clinical pipeline report, company report or official report of Turning Point Therapeutics.